Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: A twenty-four-week, open-label, dose-increasing study

Current Therapeutic Research - Clinical and Experimental

Volumn 64, Issue 4, 2003, Pages 236-247

  Homma, Yasuhiko ^a   Homma, Koichiro ^b   Iizuka, Shinichi ^a   Iigaya, Kamon ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecules; Carotid arteriosclerosis; Fluvastatin; Lipoprotein subfractions; Oxidized LDL; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CELL ADHESION MOLECULE; CHOLESTEROL ESTER TRANSFER PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; SOLUBLE CELL ADHESION MOLECULE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PLASMA; PRIORITY JOURNAL; SIDE EFFECT; TRANSPORT KINETICS; ULTRACENTRIFUGATION;

EID: 0038509017     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(03)00060-2     Document Type: Article

References (50)

1. Goldstein LJ, Brown MS. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res. 1984;25:1450-1461.
2. Havel RJ, Kane JP. Introduction. I. Structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AC, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:2705-2716.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
7. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
8. Gaw A, Packard CJ, Murray EF, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13:170-189.
9. Homma Y, Ozawa H, Kobayashi T, et al. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer proteins in type II hyperlipoproteinemia. Atherosclerosis. 1995;114:223-234.
10. Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis. 1999;146:167-174.
11. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies. Atherosclerosis. 1992;93:105-113.
12. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoprotein by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165:335-338.
13. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT. The Kupio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C.
14. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 1997;128:11-18.
15. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844.
16. Bustos C, Hernandez-Presa MA, Ortega M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
17. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2001;21:115-121.
18. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993;13:571-578.
19. Corsini A, Pazzucconi F, Pfister P, et al. Inhibition of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 1996;348:1584. Letter.
20. Negre-Aminou P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259-268.
21. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
22. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17:1521-1526.
23. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J Investig Med. 2000;48:183-189.
24. Larsen E, Celi A, Gilbert GE, et al. PAGDEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59:305-312.
25. Mayadas TN, Johnson RC, Rayburn H, et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993;74:541-554.
26. Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res. 1981;22:1206-1213.
27. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255-1274.
28. Noma A, Hata Y, Goto Y. Quantification of serum apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy Japanese by turbidimetric immunoassay: Reference values and age- and sex-related differences. Clin Chim Acta. 1991;199:147-157.
29. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-595.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
31. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100, and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
32. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultra-centrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
33. Nagasaki T, Akanuma Y. A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta. 1977;75:371-375.
34. The Instruction Manual for Quantitative Cholesteryl Ester Transfer Protein (CETP) ELISA Assay. Westminster, Colo: REAADS Medical Products; 1996.
35. Kotani R, Maekawa M, Kanno T, et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta. 1994;1215:121-125.
36. Craig WY, Poulin SE, Nelson CP, Ritchie RF. ELISA of IgG antibody to oxidized low-density lipoprotein: Effects of blocking buffer and method of data expression. Clin Chem. 1994;40:882-888.
37. Instruction Manuals for Determining Plasma Levels of sLCAM-1, sVCAM-1, and sP-selectin with ELISA Method. Vienna, Austria: Bender MedSystems; 1997.
38. Ranganathan S, Hattori H, Kashyap ML. A rapid flow cytometric assay for low-density lipoprotein receptors in human peripheral blood mononuclear cells. J Lab Clin Med. 1995;125:479-486.
39. Kataoka S, Paichi M, Howard BV. Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem. 1994;40:11-13.
40. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
41. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol. 1998;81:582-587.
42. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999;144:263-270.
43. Saito Y, Goto Y, Nakaya N, et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis. 1988;72:205-211.
44. Hanninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis. 1990;85:81-89.
45. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189-199.
46. Sevanian A, Hwang J, Hodis H, et al. Contribution of in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol. 1996;16:784-793.
47. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
48. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
49. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:441-445.
50. Bui MN, Sack MN, Moutsatsos G, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J. 1996;131:663-667.